Menarini was established over a century ago (1886 to be precise) in a small laboratory of the Farmacia Internazionale (International Pharmacy) of Naples. In 1915 it transferred to Florence, where it still has its head office.

Since 1978 Menarini has established a series of agreements with some important Italian companies, with the aim of joining energy and resources to compete better at international level.

The first agreement was with Malesci, then followed those with Guidotti, Lusofarmaco, Lusochimica and FIRMA. The aim of these agreements has been a better organization of the strategic areas of Research and Development and of Internationalization, as well as reachin maximum efficiency in the production and supply chain.

In 1976, activity in the Diagnostics Division was added to the existing ethical drug production and in 1994 the OTC Division was started.

Already in the 1960�s Menarini had realised the importance of broadening its horizons beyond its domestic borders. In fact, the establishment of Laboratorios Menarini of Barcelona, Spain dates back to this period.

The 1970�s were characterised by the strengthening of Menarini's position in Italy which was consolidated the following decade by numerous agreements made with other important Italian pharmaceutical companies.

Once Menarini reached the first position in the ranking of Italian pharmaceutical companies in the 1990's, it focussed on its rapid expansion throughout Europe and the world through the acquisition or opening of affiliate companies.

Today the Menarini Group is present:

Since 1978, the year in which the possibility of patenting drugs was introduced into Italian law (which in practical terms means the possibility of having returns from research investments), Menarini has been able to formulate a strategic plan for a wide-reaching industrial programme. Thus began the heavy investments in the Research and Development (R&D) of new drugs. In 1978 Menarini only had 11 employees in R&D; now they number just under 800, with an annual investment of about 180 billion Italian Lira (93 million Euro), the equivalent of 11% of the ethical drug turnover. The Research activity of the Menarini Group centres on a single pole, Menarini Ricerche, which deals with all R&D activities from the initial stage of new projects to the registration stage. 
The Menarini Group has constantly pursued two strategic objectives: Research and Internationalisation. Both are bearing excellent fruit, and will allow the company itself to place the drugs of its own research at the disposal of patients all over the world.

A deep-rooted history and philosophy of international agreements with other companies through the licensing of innovative products forms the basis of these two strategic objectives. This has been fundamental both for the implementation of Menarini�s own strategies and for the sharing of a huge body of international scientific culture.
Today, indeed, the Menarini Group has many licensing partners for the European market and an excellent reputation as an effective and efficient partner, both in the development of new products and in the realm of scientific information

Today the Menarini Group is the first Italian pharmaceutical group in the world.

The Menarini Group has now long been the top Pharmaceutical Group in Italy and has taken important positions on the European and pharmaceutical market.

PAMELA Pharmaceutical Industries was established in 1982 in natural surroundings in the suburb of Damascus, namely Delba in Syria, in an area of 12,000 square meters. This area is the best specified spot for industries.

PAMELA Pharmaceutical has been established under the shadow of Messrs. Damco, who has a vast experience in their business for over 25 years in the pharmaceutical trade in items like Suppositories, Dry Sprays, Syrup Lines, Capsules, Tablets and Ointments by utilizing the best and modern high technological techniques and machines from Germany.

It analyses raw materials in three laboratories for Microbial, Primary and Chemicals.

PAMELA Pharmaceutical Industries has a wide range of products line which include Cardiovascular Drugs, Digestive Drugs, Physiological and Neurological drugs. Respiratory drugs, Antibiotics and Antirheumatic.

[Is an Arabic Tunisian Pharmaceutical Company Specialized in the manufacturing of Drops in different Pharmaceutical forms such as Eye Drops, Nose Drops etc.

All Pharma Products manufactured by Unimed are authorized by the Tunisian Ministry of Health and the Company follow Good Manufacturing Practice (GMP).